Key facts
- It has raised $65.3M; the latest was Later Stage VC ($40.0M) in Sep 2025.
- Notable investors include Alumni Ventures, Innovate UK, Mana Ventures, Gaingels, EDBI — 21 tracked in total.
- Status: Privately Held (backing).
Leadership
- Andrew HarleyChief Financial Officer
- Eric SchloesserExecutive
- Jennifer XistrisChief Human Resources Officer
- Michael BauerExecutive Officer
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Leo Cancer Care
- ·The full record, as it builds
Funding rounds
No funding rounds for Leo Cancer Care are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leo Cancer Care
Developer of a cancer treatment system designed to simplify cancer radiation therapy. The company's system can be integrated with a radiotherapy machine specializing in three-dimensional image capturing, controlling radiation beams, and automatically delivering the right amount of energy to the right tissue, enabling cancer care centers to reduce the pain and cost of chemo and radiation therapy.
- Sector
- Healthcare
- HQ
- Crawley, United Kingdom
- Founded
- 2018
- Employees
- 52
- Website
- leocancercare.com/
- Ownership
- Privately Held (backing)
Leo Cancer Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leo Cancer Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leo Cancer Care in its N-PORT filings yet. We sweep new filings monthly.